Oxford Nanopore Technologies Past Earnings Performance
Past criteria checks 0/6
Oxford Nanopore Technologies's earnings have been declining at an average annual rate of -16.9%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 6.8% per year.
Key information
-16.9%
Earnings growth rate
-12.3%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 6.8% |
| Return on equity | -27.5% |
| Net Margin | -94.8% |
| Next Earnings Update | 04 Mar 2025 |
Recent past performance updates
Recent updates
The Price Is Right For Oxford Nanopore Technologies plc (LON:ONT)
Dec 19
Investors Appear Satisfied With Oxford Nanopore Technologies plc's (LON:ONT) Prospects As Shares Rocket 33%
Sep 20Revenues Tell The Story For Oxford Nanopore Technologies plc (LON:ONT) As Its Stock Soars 30%
Jul 23What You Can Learn From Oxford Nanopore Technologies plc's (LON:ONT) P/SAfter Its 25% Share Price Crash
Apr 26Oxford Nanopore Technologies plc (LON:ONT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 09Oxford Nanopore Technologies plc's (LON:ONT) Share Price Matching Investor Opinion
Mar 08Companies Like Oxford Nanopore Technologies (LON:ONT) Are In A Position To Invest In Growth
Jul 12With Oxford Nanopore Technologies plc (LON:ONT) It Looks Like You'll Get What You Pay For
May 14Companies Like Oxford Nanopore Technologies (LON:ONT) Are In A Position To Invest In Growth
Apr 06Companies Like Oxford Nanopore Technologies (LON:ONT) Can Afford To Invest In Growth
Dec 22New Forecasts: Here's What Analysts Think The Future Holds For Oxford Nanopore Technologies plc (LON:ONT)
Sep 19We Think Oxford Nanopore Technologies (LON:ONT) Can Easily Afford To Drive Business Growth
Sep 16Revenue & Expenses Breakdown
How Oxford Nanopore Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 168 | -159 | 154 | 102 |
| 31 Mar 24 | 169 | -157 | 154 | 103 |
| 31 Dec 23 | 170 | -155 | 155 | 103 |
| 30 Sep 23 | 166 | -143 | 156 | 95 |
| 30 Jun 23 | 162 | -131 | 157 | 88 |
| 31 Mar 23 | 180 | -111 | 149 | 74 |
| 31 Dec 22 | 199 | -91 | 141 | 59 |
| 30 Sep 22 | 198 | -122 | 160 | 62 |
| 30 Jun 22 | 197 | -153 | 179 | 65 |
| 31 Mar 22 | 165 | -160 | 170 | 70 |
| 31 Dec 21 | 134 | -168 | 162 | 76 |
| 30 Sep 21 | 129 | -119 | 121 | 66 |
| 30 Jun 21 | 125 | -71 | 80 | 55 |
| 31 Mar 21 | 119 | -66 | 76 | 52 |
| 31 Dec 20 | 114 | -61 | 71 | 49 |
| 31 Dec 19 | 52 | -72 | 66 | 40 |
| 31 Dec 18 | 33 | -53 | 42 | 37 |
| 31 Dec 17 | 14 | -57 | 38 | 35 |
| 31 Dec 16 | 5 | -59 | 26 | 38 |
| 31 Dec 15 | 1 | -39 | 17 | 27 |
| 31 Dec 14 | 0 | -37 | 13 | 28 |
Quality Earnings: ONT is currently unprofitable.
Growing Profit Margin: ONT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONT is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare ONT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).
Return on Equity
High ROE: ONT has a negative Return on Equity (-27.49%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 02:12 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oxford Nanopore Technologies plc is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Blanka Porkolab | Barclays |
| Hassan Al-Wakeel | Barclays |
| Odysseas Manesiotis | Berenberg |